Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
BMC Urol ; 24(1): 7, 2024 Jan 03.
Article in English | MEDLINE | ID: mdl-38172746

ABSTRACT

BACKGROUND: To discuss the impact of overactive bladder (OAB) on medical students. overactive bladder. is a chronic condition that causes sudden and intense urges to urinate, which can have significant physical and psychological effects on patients' lives. The prevalence of OAB among medical students is relatively high, with some studies reporting rates as high as 35.4%. This research aims to shed light on the prevalence rates and risk factors associated with OAB among medical students in Jordan. METHODS: A cross-sectional study was conducted using an online self-reported questionnaire as the study tool. The questionnaire collected the sociodemographic, health, and academic characteristics of medical students, as well as the new 7-item OABSS score. RESULTS: Out of the total sample of medical students surveyed (n = 525), 44.5% reported experiencing symptoms of OAB. Furthermore, the analysis also revealed that there was a significant difference in the prevalence of OAB between the ages of medical students. In addition, the study also found that there was a significant association between OAB symptoms and basic years, positive history of diagnostic UTI, positive history of recent trauma, high stress, and taking certain medications. CONCLUSIONS: The study highlights the need for further research in this area and emphasizes the possible implications of OAB for medical students, including the need for additional support and resources to manage the condition.


Subject(s)
Students, Medical , Urinary Bladder, Overactive , Humans , Urinary Bladder, Overactive/drug therapy , Cross-Sectional Studies , Prevalence , Jordan/epidemiology , Risk Factors , Surveys and Questionnaires
3.
Mutagenesis ; 35(4): 319-330, 2020 09 12.
Article in English | MEDLINE | ID: mdl-32780103

ABSTRACT

Following advancements in the field of genotoxicology, it has become widely accepted that 3D models are not only more physiologically relevant but also have the capacity to elucidate more complex biological processes that standard 2D monocultures are unable to. Whilst 3D liver models have been developed to evaluate the short-term genotoxicity of chemicals, the aim of this study was to develop a 3D model that could be used with the regulatory accepted in vitro micronucleus (MN) following low-dose, longer-term (5 days) exposure to engineered nanomaterials (ENMs). A comparison study was carried out between advanced models generated from two commonly used liver cell lines, namely HepaRG and HepG2, in spheroid format. While both spheroid systems displayed good liver functionality and viability over 14 days, the HepaRG spheroids lacked the capacity to actively proliferate and, therefore, were considered unsuitable for use with the MN assay. This study further demonstrated the efficacy of the in vitro 3D HepG2 model to be used for short-term (24 h) exposures to genotoxic chemicals, aflatoxin B1 (AFB1) and methyl-methanesulfonate (MMS). The 3D HepG2 liver spheroids were shown to be more sensitive to DNA damage induced by AFB1 and MMS when compared to the HepG2 2D monoculture. This 3D model was further developed to allow for longer-term (5 day) ENM exposure. Four days after seeding, HepG2 spheroids were exposed to Zinc Oxide ENM (0-2 µg/ml) for 5 days and assessed using both the cytokinesis-block MN (CBMN) version of the MN assay and the mononuclear MN assay. Following a 5-day exposure, differences in MN frequency were observed between the CBMN and mononuclear MN assay, demonstrating that DNA damage induced within the first few cell cycles is distributed across the mononucleated cell population. Together, this study demonstrates the necessity to adapt the MN assay accordingly, to allow for the accurate assessment of genotoxicity following longer-term, low-dose ENM exposure.


Subject(s)
Cell Culture Techniques/methods , Liver/drug effects , Micronucleus Tests/methods , Mutagens/toxicity , Spheroids, Cellular , Aflatoxin B1/toxicity , Cell Line , Hep G2 Cells , Hepatocytes/drug effects , Humans , Methyl Methanesulfonate/toxicity , Models, Biological
4.
Diabetes Metab Syndr ; 13(4): 2689-2697, 2019.
Article in English | MEDLINE | ID: mdl-31405695

ABSTRACT

BACKGROUND: The metabolic syndrome (Metabolic syndrome) is a cluster of the most dangerous risk factors for type 2 diabetes mellitus and cardiovascular diseases (CVD), two of the main causes of morbidity and mortality worldwide, which include hyperglycemia, abdominal obesity, lipid abnormalities and high blood pressure. STUDY DESIGN: a cross-sectional descriptive study. RESULTS: A predominant number (94.1%) knew what constitutes MS. However, merely more than a quarter of the participant (28%) knew correctly the serum LDL cutoff value for the diagnosis of MS according to IDF criteria. The aim of lipid lowering treatment was known by slightly more than three fourth (78%) of the participants. Two third also knew the target of antihypertensive therapy. More than two third (69.5%) were also aware that waist circumference is one of the criteria for diagnosis of Metabolic syndrome. CONCLUSION: There is a need to increase the awareness of MS among the PHC Physicians. More training programs need to be planned. A better awareness among primary care physician is warranted for an early diagnosis and effective management of MS in Saudi Arabia.


Subject(s)
Biomarkers/analysis , Health Knowledge, Attitudes, Practice , Mass Screening , Metabolic Syndrome/diagnosis , Metabolic Syndrome/prevention & control , Physicians, Primary Care/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Adult , Attitude of Health Personnel , Cross-Sectional Studies , Disease Management , Female , Follow-Up Studies , Humans , Male , Physicians, Primary Care/psychology , Physicians, Primary Care/standards , Pilot Projects , Prognosis , Saudi Arabia , Surveys and Questionnaires
5.
Int J Mol Sci ; 17(3): 395, 2016 Mar 17.
Article in English | MEDLINE | ID: mdl-26999117

ABSTRACT

Recent genome-wide association studies identified single nucleotide polymorphisms (SNPs) on the chromosome 9p21.3 conferring the risk for CAD (coronary artery disease) in individuals of Caucasian ancestry. We performed a genetic association study to investigate the effect of 12 candidate SNPs within 9p21.3 locus on the risk of CAD in the Saudi population of the Eastern Province of Saudi Arabia. A total of 250 Saudi CAD patients who had experienced an myocardial infarction (MI) and 252 Saudi age-matched healthy controls were genotyped using TaqMan assay. Controls with evidenced lack of CAD provided 90% of statistical power at the type I error rate of 0.05. Five percent of the results were rechecked for quality control using Sanger sequencing, the results of which concurred with the TaqMan genotyping results. Association analysis of 12 SNPs indicated a significant difference in the genotype distribution for four SNPs between cases and controls (rs564398 p = 0.0315, χ² = 4.6, odds ratio (OD) = 1.5; rs4977574 p = 0.0336, χ² = 4.5, OD = 1.4; rs2891168 p = 1.85 × 10 - 10, χ² = 40.6, OD = 2.1 and rs1333042 p = 5.14 × 10 - 9, χ² = 34.1, OD = 2.2). The study identified three protective haplotypes (TAAG p = 1.00 × 10 - 4; AGTA p = 0.022 and GGGCC p = 0.0175) and a risk haplotype (TGGA p = 2.86 × 10 - 10) for the development of CAD. This study is in line with others that indicated that the SNPs located in the intronic region of the CDKN2B-AS1 gene are associated with CAD.


Subject(s)
Coronary Artery Disease/genetics , Myocardial Infarction/genetics , Polymorphism, Single Nucleotide , RNA, Long Noncoding/genetics , Adult , Aged , Case-Control Studies , Female , Humans , Introns , Male , Middle Aged , Saudi Arabia
6.
PLoS One ; 11(2): e0146502, 2016.
Article in English | MEDLINE | ID: mdl-26849363

ABSTRACT

Coronary Artery Disease (CAD) remains the leading cause of mortality worldwide. Mortality rates associated with CAD have shown an exceptional increase particularly in fast developing economies like the Kingdom of Saudi Arabia (KSA). Over the past twenty years, CAD has become the leading cause of death in KSA and has reached epidemic proportions. This rise is undoubtedly caused by fast urbanization that is associated with a life-style that promotes CAD. However, the question remains whether genetics play a significant role and whether genetic susceptibility is increased in KSA compared to the well-studied Western European populations. Therefore, we performed an Exome-wide association study (EWAS) in 832 patients and 1,076 controls of Saudi Arabian origin to test whether population specific, strong genetic risk factors for CAD exist, or whether the polygenic risk score for known genetic risk factors for CAD, lipids, and Type 2 Diabetes show evidence for an enriched genetic burden. Our results do not show significant associations for a single genetic locus. However, the heritability estimate for CAD for this population was high (h(2) = 0.53, S.E. = 0.1, p = 4e(-12)) and we observed a significant association of the polygenic risk score for CAD that demonstrates that the population of KSA, at least in part, shares the genetic risk associated to CAD in Western populations.


Subject(s)
Coronary Artery Disease/epidemiology , Coronary Artery Disease/genetics , Exome , Genome-Wide Association Study , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Analysis of Variance , Female , Genetic Predisposition to Disease , Genotype , High-Throughput Nucleotide Sequencing , Humans , Inheritance Patterns , Male , Middle Aged , Polymorphism, Single Nucleotide , Quantitative Trait, Heritable , Risk Factors , Saudi Arabia/epidemiology , Young Adult
7.
Toxicol Sci ; 144(2): 246-58, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25601991

ABSTRACT

Toxicity of nanoparticles (NPs) is often correlated with the physicochemical characteristics of the materials. However, some discrepancies are noted in in-vitro studies on quantum dots (QDs) with similar physicochemical properties. This is partly related to variations in cell type. In this study, we show that epithelial (BEAS-2B), fibroblast (HFF-1), and lymphoblastoid (TK6) cells show different biological responses following exposure to QDs. These cells represented the 3 main portals of NP exposure: bronchial, skin, and circulatory. The uptake and toxicity of negatively and positively charged CdSe:ZnS QDs of the same core size but with different surface chemistries (carboxyl or amine polymer coatings) were investigated in full and reduced serum containing media following 1 and 3 cell cycles. Following thorough physicochemical characterization, cellular uptake, cytotoxicity, and gross chromosomal damage were measured. Cellular damage mechanisms in the form of reactive oxygen species and the expression of inflammatory cytokines IL-8 and TNF-α were assessed. QDs uptake and toxicity significantly varied in the different cell lines. BEAS-2B cells demonstrated the highest level of QDs uptake yet displayed a strong resilience with minimal genotoxicity following exposure to these NPs. In contrast, HFF-1 and TK6 cells were more susceptible to toxicity and genotoxicity, respectively, as a result of exposure to QDs. Thus, this study demonstrates that in addition to nanomaterial physicochemical characterization, a clear understanding of cell type-dependent variation in uptake coupled to the inherently different capacities of the cell types to cope with exposure to these exogenous materials are all required to predict genotoxicity.


Subject(s)
Cadmium Compounds/chemistry , Quantum Dots , Selenium Compounds/chemistry , Sulfides/chemistry , Zinc Compounds/chemistry , Cadmium Compounds/toxicity , Cell Line , Flow Cytometry , Humans , Microscopy, Electron, Scanning Transmission , Selenium Compounds/toxicity , Sulfides/toxicity , Zinc Compounds/toxicity
9.
Catheter Cardiovasc Interv ; 76(2): 165-73, 2010 Aug 01.
Article in English | MEDLINE | ID: mdl-20665855

ABSTRACT

BACKGROUND: Coronary artery disease (CAD) negatively impacts prognosis of patients undergoing surgical aortic valve replacement and revascularization is generally recommended at the time of surgery. Implications of CAD and preprocedural revascularization in the setting of transcatheter aortic valve implantation (TAVI) are not known. METHOD: Patients who underwent successful TAVI from January 2005 to December 2007 were retrospectively divided into five groups according to the extent of CAD assessed with the Duke Myocardial Jeopardy Score: no CAD, CAD with DMJS 0, 2, 4, and > or =6. Study endpoints included 30-day and 1-year survival, evolution of symptoms, left ventricular ejection fraction (LVEF), and mitral regurgitation (MR) and need of revascularization during follow-up. RESULTS: One hundred and thirty-six patients were included, among which 104 (76.5%) had coexisting CAD. Thirty-day mortality in the five study groups was respectively 6.3, 14.6, 7.1, 5.6, and 17.7% with no statistically significant difference between groups (P = 0.56). Overall survival rate at one year was 77.9% (95% CL: 70.9, 84.9) with no difference between groups (P = 0.63). Symptoms, LVEF, and MR all significantly improved in the first month after TAVI, but the extent of improvement did not differ between groups (P > 0.08). Revascularization after TAVI was uncommon. CONCLUSION: The presence of CAD or nonrevascularized myocardium was not associated with an increased risk of adverse events in this initial cohort. On the basis of these early results, complete revascularization may not constitute a prerequisite of TAVI. This conclusion will require re-assessment as experience accrues in patients with extensive CAD.


Subject(s)
Aortic Valve , Coronary Artery Disease/complications , Heart Valve Diseases/therapy , Heart Valve Prosthesis Implantation/methods , Aged , Aged, 80 and over , Aortic Valve/physiopathology , British Columbia , Cardiac Catheterization/adverse effects , Cardiac Catheterization/mortality , Chi-Square Distribution , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Coronary Artery Disease/therapy , Female , Heart Valve Diseases/complications , Heart Valve Diseases/mortality , Heart Valve Diseases/physiopathology , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/mortality , Humans , Kaplan-Meier Estimate , Logistic Models , Male , Mitral Valve Insufficiency/etiology , Myocardial Revascularization , Odds Ratio , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Stroke Volume , Survival Rate , Time Factors , Treatment Outcome , Ventricular Function, Left
10.
BMJ Case Rep ; 20102010 Nov 12.
Article in English | MEDLINE | ID: mdl-22798447

ABSTRACT

Hepatic lipase (HL) deficiency is a rare genetic disorder that has been associated with premature atherosclerosis despite high plasma high-density lipoprotein (HDL) cholesterol concentrations in the affected individuals. The authors describe the clinical and biochemical features of HL deficiency in a young male of Middle-Eastern-Arabic origin. This is the first report of cholesterol ester transfer protein (CETP) activity and mass in HL deficiency in a patient from this ethnic group. While the CETP mass was high, its activity was low, a discrepancy likely due to the abnormal composition of patient's HDL particles.


Subject(s)
Arabs/genetics , Lipase/deficiency , Adult , Fluorobenzenes/therapeutic use , Genetic Diseases, Inborn/diagnosis , Genetic Diseases, Inborn/genetics , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Lipase/genetics , Lipoproteins, HDL/blood , Male , Middle East , Pyrimidines/therapeutic use , Rosuvastatin Calcium , Sulfonamides/therapeutic use
11.
J Am Coll Cardiol ; 53(20): 1855-8, 2009 May 19.
Article in English | MEDLINE | ID: mdl-19442884

ABSTRACT

OBJECTIVES: We describe procedural and clinical outcomes in a high-risk cohort undergoing transcatheter aortic valve replacement with early next-generation transcatheter valve and delivery systems. BACKGROUND: Percutaneous aortic valve replacement is gaining acceptance as a viable option in patients at high surgical risk. Broader application will require further advances in valve and delivery system technology. METHODS: Transarterial aortic valve replacement was attempted in 25 patients (mean age 85 years) determined to be at high surgical risk due to comorbidities. A new delivery catheter system (RetroFlex 2, Edwards Lifesciences, Irving, California) was utilized in combination with either a balloon-expandable SAPIEN (Edwards Lifesciences) valve or a next-generation low-profile cobalt-chromium bovine pericardial SAPIEN XT (Edwards Lifesciences) valve. RESULTS: Percutaneous valve replacement was successful in all 25 high-risk patients. Aortic valve area increased from 0.59 +/- 0.15 cm(2) to 1.60 +/- 0.27 cm(2). In this high-risk cohort (Society of Thoracic Surgeons and logistic EuroSCORE estimates of surgical mortality were 8.9% and 21.0%, respectively), 30-day mortality was 0%. CONCLUSIONS: Technical and procedural advances in catheter systems and prosthetic valves designed for percutaneous aortic valve delivery may contribute to increased procedural success and improved clinical outcomes.


Subject(s)
Aortic Valve Stenosis/surgery , Cardiac Catheterization/instrumentation , Heart Valve Prosthesis Implantation/instrumentation , Aged , Aged, 80 and over , Equipment Design , Female , Femoral Artery/surgery , Follow-Up Studies , Heart Valve Prosthesis , Humans , Male , Postoperative Complications/prevention & control , Punctures , Treatment Outcome
12.
Am J Cardiol ; 103(9): 1295-301, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19406275

ABSTRACT

Transcatheter aortic valve replacement (TAVR) required precise knowledge of the anatomic dimensions and physical characteristics of the aortic valve, annulus, and aortic root. Most groups currently use angiography, transthoracic echocardiography (TTE), or transesophageal echocardiography (TEE) to assess aortic annulus dimensions and anatomy. However, multislice computed tomography (MSCT) may allow more detailed 3-dimensional assessment of the aortic root. Twenty-six patients referred for TAVR underwent MSCT. Scans were also obtained for 18 patients after TAVR. All patients underwent pre- and postprocedural aortic root angiography, TTE, and TEE. Mean differences in measured aortic annular diameters were 1.1 mm (95% confidence interval 0.5, 1.8) for calibrated angiography and TTE, -0.9 mm (95% confidence interval -1.7, -0.1 mm) for TTE and TEE, -0.3 mm (95% confidence interval -1.1, 0.6 mm) for MSCT (sagittal) and TTE, and -1.2 mm (95% confidence interval -2.2, -0.2 mm) for MSCT (sagittal) and TEE. Coronal systolic measurements using MSCT, which corresponded to angiographic orientation, were 3.2 mm (1st and 3rd quartiles 2.6, 3.9) larger than sagittal systolic measurements, which were in the same anatomic plane as standard TTE and TEE views. There was no significant association between either shape of the aortic annulus or amount of aortic valve calcium and development of perivalvular aortic regurgitation. After TAVR, the prosthesis extended to or beyond the inferior border of the left main ostium in 9 of 18 patients (50%), and in 11 patients (61%), valvular calcium was <5 mm from the left main ostium. In conclusion, MSCT identified that the aortic annulus was commonly eccentric and often oval. This may in part explain the small, but clinically insignificant, differences in measured aortic annular diameters with other imaging modalities. MSCT after TAVR showed close proximity of both the prosthesis and displaced valvular calcium to the left main ostium in most patients. Neither eccentricity nor calcific deposits appeared to contribute significantly to severity of paravalvular regurgitation after TAVR.


Subject(s)
Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Heart Valve Prosthesis Implantation/methods , Imaging, Three-Dimensional/methods , Tomography, X-Ray Computed/methods , Aged , Aged, 80 and over , Cardiac Catheterization/methods , Cohort Studies , Echocardiography/methods , Echocardiography, Transesophageal/methods , Female , Follow-Up Studies , Heart Valve Diseases/diagnosis , Heart Valve Diseases/surgery , Humans , Male , Middle Aged , Minimally Invasive Surgical Procedures/methods , Risk Assessment , Sensitivity and Specificity , Severity of Illness Index , Treatment Outcome
13.
J Thorac Cardiovasc Surg ; 137(1): 167-73, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19154921

ABSTRACT

BACKGROUND: We reported the first case of successful transapical transcatheter aortic valve implantation in a human subject in 2005 and have now completed a 12-month follow-up on our first 26 patients. This is, to date, the longest follow-up of patients undergoing transapical aortic valve implantation. METHODS: Between October 2005 and January 2007, 26 patients (13 female) underwent transcatheter transapical aortic valve implantation with either 23- or 26-mm Edwards Lifesciences transcatheter bioprostheses. All patients with symptomatic aortic stenosis were declined for conventional aortic valve replacement because of unacceptable operative risks and were not candidates for transfemoral aortic valve implantation because of poor arterial access. Clinical and echocardiographic follow-up was performed before discharge and at 1, 6, and 12 months. Data from the 17 patients who survived over 12 months were used for comparisons of the baseline and follow-up results. RESULTS: The mean age was 80 +/- 9 years, and the predicted operative mortality was 37% +/- 20% by using logistic EuroSCORE and 11% +/- 6% by using the Society of Thoracic Surgeons Risk Calculator. Valves were successfully implanted in all patients. Six patients died within 30 days (30-day mortality, 23%), and 3 patients died from noncardiovascular causes after 30 days (late mortality, 12%). Among patients who survived at least 30 days, 12-month survival was 85%. There were no late valve-related complications. New York Heart Association functional class improved significantly. The aortic valve area and mean gradient remained stable at 12 months (1.6 +/- 0.3 cm(2) and 9.6 +/- 4.8 mm Hg, respectively). CONCLUSION: Our 1-year clinical and echocardiographic outcomes suggest that transapical transcatheter aortic valve implantation is a viable alternative to conventional aortic valve replacement in selected high-risk patients.


Subject(s)
Aortic Valve/surgery , Heart Valve Prosthesis Implantation/methods , Aged , Aged, 80 and over , Aortic Valve/diagnostic imaging , Cardiac Catheterization , Female , Follow-Up Studies , Humans , Male , Middle Aged , Time Factors , Treatment Outcome , Ultrasonography
14.
Catheter Cardiovasc Interv ; 72(4): 573-8, 2008 Oct 01.
Article in English | MEDLINE | ID: mdl-18819120

ABSTRACT

OBJECTIVES: Early clinical outcomes in selected high-risk patients undergoing catheter-based aortic valve replacement (AVR) compare favorably with conventional surgical AVR. Improved understanding of the mechanisms of success and failure of transcatheter AVR will likely improve outcomes further. To this end, we examined our experience during the developmental phases of transcatheter AVR and describe the causes and management of prosthetic valve malposition. METHODS: Transcatheter balloon-expandable AVR was performed in 170 patients at two centers. Malposition was defined as prosthetic valve implantation in a location other than within the native valve. Patients were prospectively identified and followed as part of an ongoing database. RESULTS: Valve malposition occurred in 9 of 170 patients (5.3%). Final position was supravalvular in eight of nine cases. In all cases, embolization to the ascending aorta occurred within a few cardiac cycles following deployment. Importantly, late embolization was not observed. In most cases, the prosthesis was uneventfully repositioned in the more distal aorta. Positioning was subvalvular in one patient (0.6%), resulting in a severe regurgitation with residual native valve stenosis. Implantation of a second transcatheter valve was attempted in six patients and was successful in all. Conventional AVR was performed in two patients, with early mortality in one. At late follow-up (mean 412 days), seven of nine patients remain alive (78%) with a functioning prosthesis and relief of aortic stenosis. CONCLUSIONS: Malposition of current balloon-expandable aortic valves is a largely preventable complication. An improved understanding of the procedure will likely minimize this possibility and mitigate the consequences should malposition occur.


Subject(s)
Aortic Valve Stenosis/therapy , Aortic Valve , Cardiac Catheterization/adverse effects , Catheterization/adverse effects , Foreign-Body Migration/therapy , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis , Aged , Aged, 80 and over , Aortic Valve Stenosis/diagnostic imaging , Canada , Cardiac Catheterization/instrumentation , Catheterization/instrumentation , Device Removal , Foreign-Body Migration/diagnostic imaging , Foreign-Body Migration/etiology , Foreign-Body Migration/mortality , Foreign-Body Migration/prevention & control , Heart Valve Prosthesis Implantation/instrumentation , Humans , Prospective Studies , Prosthesis Design , Prosthesis Failure , Radiography, Interventional , Time Factors , Treatment Outcome
15.
Can J Cardiol ; 24(4): e25-6, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18401478

ABSTRACT

A 70-year-old man presented with a non-ST elevation myocardial infarction attributable to a 99% occlusion of his mid-left anterior descending artery and concomitant symptoms suggestive of giant cell arteritis. He underwent bare metal stenting, with an excellent angiographic result, and was placed on dual antiplatelet therapy, as well as oral prednisone 30 mg twice daily, while awaiting confirmatory temporal artery biopsy. Unfortunately, 70 h after percutaneous coronary intervention, he developed acute stent thrombosis. Platelet aggregometry demonstrated that he was responsive to acetylsalicylic acid, but marginally responsive to clopidogrel. Over the next 30 days, he had a marked clinical improvement, with an improvement in platelet response to clopidogrel that paralleled the clinical resolution of his vasculitis. The present case reports the first incidence of acute stent thrombosis associated with giant cell arteritis, and suggests that the proinflammatory milieu of acute inflammatory arthritides may warrant prolonged, aggressive antiplatelet therapy in the setting of an acute coronary syndrome.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Artery Disease/diagnosis , Coronary Thrombosis/diagnosis , Giant Cell Arteritis/diagnosis , Myocardial Infarction/therapy , Stents , Aged , Aspirin/therapeutic use , Clopidogrel , Coronary Angiography , Coronary Artery Disease/drug therapy , Coronary Thrombosis/drug therapy , Giant Cell Arteritis/drug therapy , Humans , Male , Platelet Aggregation Inhibitors/therapeutic use , Prednisone/therapeutic use , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use
16.
Can J Cardiol ; 22(14): 1233-7, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17151774

ABSTRACT

Although the etiology of eosinophilic myocarditis (EM) is not always apparent, several causes are identified, including hypersensitivity to a drug or substance, with the heart as the target organ. However, symptoms and signs of hypersensitivity are not found in all patients. EM can lead to progressive myocardial damage with destruction of the conduction system and refractory heart failure. The present report describes three cases of biopsy-proven EM with different presentations, including acute coronary syndrome, cardiogenic shock and newly diagnosed heart failure. In one patient, hypersensitivity to sumatriptan was suspected to be the underlying cause. All patients responded well to treatment with steroids, angiotensin-converting enzyme inhibitors and beta-blockers. There was a complete recovery of the ventricular function in all cases.


Subject(s)
Eosinophilia/diagnosis , Myocarditis/diagnosis , Adrenergic beta-Antagonists/therapeutic use , Adult , Angina, Unstable/drug therapy , Angina, Unstable/etiology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Eosinophilia/chemically induced , Eosinophilia/drug therapy , Glucocorticoids/therapeutic use , Heart Failure/drug therapy , Heart Failure/etiology , Humans , Male , Middle Aged , Myocardial Infarction/drug therapy , Myocardial Infarction/etiology , Myocarditis/chemically induced , Myocarditis/drug therapy , Myocardium/pathology , Necrosis , Prednisone/therapeutic use , Serotonin Receptor Agonists/adverse effects , Shock, Cardiogenic/drug therapy , Shock, Cardiogenic/etiology , Sumatriptan/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...